John C Perez

US Patent:

20080131374, Jun 5, 2008

Filed:

May 4, 2007

Appl. No.:

11/800531

Inventors:

John R. Medich - East Hanover NJ, US
Hartmut Kupper - Mutterstadt, DE
Jeffrey D. Kent - Deerfield IL, US
John L. Perez - Doylestown PA, US
Eric H. Sasso - Mountain Lakes NJ, US
Oscar Segurado - Lake Bluff IL, US
George Spencer-Green - Mountain Lakes NJ, US
Theodore Pincus - Hastings-on-Hudson NY, US

International Classification:

A61K 49/00
A61K 39/395
A61K 31/44
A61P 29/00

US Classification:

424 92, 4241721, 514354, 4241331

Abstract:

The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of rheumatoid arthritis in a subject.

US Patent:

20120171123, Jul 5, 2012

Filed:

Oct 25, 2011

Appl. No.:

13/280613

Inventors:

John R. Medich - East Hanover NJ, US
Hartmut Kupper - Mutterstadt, DE
John L. Perez - Doylestown PA, US
Jeffrey D. Kent - Deerfield IL, US
Eric H. Sasso - Mountain Lakes NJ, US
Oscar Segurado - Lake Bluff IL, US
George Spencer-Green - Mountain Lakes NJ, US
Theodore Pincus - Hastings-on-Hudson NY, US

International Classification:

A61K 39/395
A61J 1/00
A61K 31/4409
A61P 19/02
A61K 49/00

US Classification:

424 92, 4241581, 514354, 206438

Abstract:

The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of rheumatoid arthritis in a subject.

US Patent:

20210085773, Mar 25, 2021

Filed:

Dec 8, 2020

Appl. No.:

17/114802

Inventors:

- New York NY, US
Annaliesa Sybil Anderson - Upper Saddle River NJ, US
Rasappa Gounder Arumugham - Lansdale PA, US
John Erwin Farley - Chapel Hill NC, US
Leah Diane Fletcher - Geneseo NY, US
Shannon Lea Harris - Nanuet NY, US
Thomas Richard Jones - New City NY, US
Lakshmi Khandke - Nanuet NY, US
Bounthon Loun - North Reading MA, US
John Lance Perez - Doylestown PA, US
Gary Warren Zlotnick - San Antonio TX, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

A61K 39/095
A61K 39/00
C07K 14/22
A61K 39/295
A61K 47/64
A61K 39/12
A61K 47/02
A61K 47/22
A61K 47/26

Abstract:

In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

US Patent:

20200405838, Dec 31, 2020

Filed:

Sep 17, 2020

Appl. No.:

17/024618

Inventors:

- NEW YORK NY, US
Annaliesa Sybil Anderson - Upper Saddle River NJ, US
Judith Absalon - New York NY, US
Johannes Frederik Beeslaar - Farnham, GB
David Cooper - Monroe NY, US
John Erwin Farley - Chapel Hill NC, US
Leah Diane Fletcher - Geneseo NY, US
Shannon Lea Harris - Nanuet NY, US
Thomas Richard Jones - Bluffton SC, US
Isis Kanevsky - New York NY, US
Lakshmi Khandke - Nanuet NY, US
Paul Liberator - Holmdel NJ, US
John Lance Perez - Doylestown PA, US
Lynn Marie Phelan - Lake Hiawatha NJ, US
Gary Warren Zlotnick - San Antonio TX, US

Assignee:

PFIZER INC. - NEW YORK NY

International Classification:

A61K 39/095
C07K 14/22
C07K 16/12
A61K 47/18
A61K 47/10
A61K 47/26
A61K 31/7028
A61K 47/64
A61P 31/00
A61K 39/12

Abstract:

In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

US Patent:

20200164056, May 28, 2020

Filed:

Dec 5, 2019

Appl. No.:

16/704701

Inventors:

- NEW YORK NY, US
Annaliesa Sybil Anderson - Upper Saddle River NJ, US
Judith Absalon - New York NY, US
Johannes Frederik Beeslaar - Farnham, GB
David Cooper - Monroe NY, US
John Erwin Farley - Chapel Hill NC, US
Leah Diane Fletcher - Geneseo NY, US
Shannon Lea Harris - Nanuet NY, US
Thomas Richard Jones - Bluffton SC, US
Isis Kanevsky - New York NY, US
Lakshmi Khandke - Nanuet NY, US
Paul Liberator - Holmdel NJ, US
John Lance Perez - Doylestown PA, US
Lynn Marie Phelan - Lake Hiawatha NJ, US
Gary Warren Zlotnick - San Antonio TX, US

Assignee:

PFIZER INC. - NEW YORK NY

International Classification:

A61K 39/095
A61P 31/00
A61K 47/64
A61K 31/7028
A61K 47/26
A61K 47/10
A61K 47/18
C07K 16/12
C07K 14/22
A61K 39/12

Abstract:

In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

US Patent:

20190231861, Aug 1, 2019

Filed:

Nov 20, 2018

Appl. No.:

16/196150

Inventors:

- NEW YORK NY, US
Annaliesa Sybil Anderson - Upper Saddle River NJ, US
Judith Absalon - New York NY, US
Johannes Frederik Beeslaar - Farnham, GB
David Cooper - Monroe NY, US
John Erwin Farley - Chapel Hill NC, US
Leah Diane Fletcher - Geneseo NY, US
Shannon Lea Harris - Nanuet NY, US
Thomas Richard Jones - New City NY, US
Isis Kanevsky - New York NY, US
Lakshmi Khandke - Nanuet NY, US
Paul Liberator - Holmdel NJ, US
John Lance Perez - Doylestown PA, US
Lynn Marie Phelan - Lake Hiawatha NJ, US
Gary Warren Zlotnick - San Antonio TX, US

Assignee:

PFIZER INC. - NEW YORK NY

International Classification:

A61K 39/095
A61K 31/7028
C07K 14/22
A61K 47/26
A61K 47/64
A61K 47/18
C07K 16/12
A61P 31/00
A61K 47/10

Abstract:

In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

US Patent:

20180214532, Aug 2, 2018

Filed:

Jan 30, 2018

Appl. No.:

15/883334

Inventors:

- New York NY, US
Annaliesa Sybil Anderson - Upper Saddle River NJ, US
Judith Absalon - New York NY, US
Johannes Frederik Beeslaar - Farnham, GB
David Cooper - Monroe NY, US
John Erwin Farley - Chapel Hill NC, US
Leah Diane Fletcher - Geneseo NY, US
Shannon Lea Harris - Nanuet NY, US
Thomas Richard Jones - New City NY, US
Isis Kanevsky - New York NY, US
Lakshmi Khandke - Nanuet NY, US
Paul Liberator - Holmdel NJ, US
John Lance Perez - Doylestown PA, US
Lynn Marie Phelan - Lake Hiawatha NJ, US
Gary Warren Zlotnick - San Antonio TX, US

International Classification:

A61K 39/095
C07K 14/22
C07K 16/12
A61K 31/7028
A61K 47/10
A61K 47/26
A61K 47/18

Abstract:

In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

US Patent:

20180000923, Jan 4, 2018

Filed:

Feb 16, 2016

Appl. No.:

15/543232

Inventors:

- New York NY, US
Annaliesa Sybil Anderson - Upper Saddle River NJ, US
Rasappa Gounder Arumugham - Lansdale PA, US
John Erwin Farley - Chapel Hill NC, US
Leah Diane Fletcher - Geneseo NY, US
Shannon Lea Harris - Nanuet NY, US
Thomas Richard Jones - New City NY, US
Lakshmi Khandke - Nanuet NY, US
Bounthon Loun - North Reading MA, US
John Lance Perez - Doylestown PA, US
Gary Warren Zlotnick - San Antonio TX, US

International Classification:

A61K 39/095
A61K 39/12
A61K 47/22
A61K 47/64
A61K 47/26
A61K 47/02
A61K 39/00

Abstract:

In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.